Antonina E. Shchekina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonina E. Shchekina has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Gennadii Martinovich Galstyan
National Medical Research Center of Hematology
8 shared publications - Elena Parovichnikova
National Medical Research Center of Hematology
5 shared publications - Olga A. Aleshina
National Medical Research Center for Hematology, Ministry of Health of Russia
4 shared publications - Vera V. Troitskaya
National Medical Research Center for Hematology, Ministry of Health of Russia
4 shared publications - Alla Mikhailovna Kovrigina
National Medical Research Center for Hematology
2 shared publications - Daria Aleksandrovna Koroleva
National Medical Research Center for Hematology
2 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 23 (5) , 80-91
Extracorporeal membrane oxygenation in acute respiratory failure in oncohematological patients
Introduction. Pulmonary complications and acute respiratory failure (ARF) are among the most severe complications of hematologic malignancies and their treatment. When conventional respiratory support fails, extracorporeal membrane oxygenation (ECMO) may serve as a rescue therapy. However, its use in patients with hematologic malignancies remains controversial. The objective was to present a case series of veno-venous ECMO support for ARF in patients with hematologic malignancies and to evaluate the outcomes. Materials and methods. A retrospective study was conducted at the National Medical Research Center for Hematology and included adult patients with diseases of the hematopoietic system who required ECMO support for severe acute respiratory failure between 2018 and 2025. The clinical characteristics of patients, the stage and type of tumor disease, prior treatment, indices of organ dysfunction (APACHE II, SOFA), parameters of gas-exchange and hemostasis were evaluated. The etiology of pulmonary involvement was investigated, and central hemodynamic parameters, coagulation profiles and laboratory findings were monitored. Duration of ECMO support, the need for renal replacement therapy, treatment-related complications, and clinical outcomes were recorded. Descriptive statistical methods were applied; results are presented as medians with interquartile ranges. Overall survival was estimated using the Kaplan – Meier method. Results. The study cohort comprised 8 adult patients with different hematologic malignancies. Prior to ECMO initiation, all patients exhibited severe hypoxemia unresponsive to conventional respiratory support. Infectious lung injury of mixed etiology was identified in most cases, whereas neoplastic pulmonary infiltration was diagnosed in one patient. Thrombocytopenia (< 50×10⁹/L) was present in 63% of patients. The median duration of ECMO therapy was 13 days. Successful discontinuation of ECMO support was achieved in two patients. Major complications were predominantly hemorrhagic, including intracranial bleeding, and were frequently associated with significant coagulation disturbances complicating anticoagulation management. Conclusion. VV-ECMO may serve as a rescue therapy for selected patients with hematologic malignancies who develop refractory acute respiratory failure. However, its use is associated with a substantial risk of severe complications and poor outcomes. Careful patient selection is therefore essential and should consider the prognosis of the underlying disease, the likelihood of bone marrow recovery, and the potential effectiveness of antitumor therapy. Early identification of the cause of pulmonary injury and timely initiation of appropriate targeted treatment are critical factors influencing the success of ECMO support.
- 22 October 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 23 (5) , 80-91
Open AccessExtracorporeal membrane oxygenation in acute respiratory failure in oncohematological patients
Introduction. Pulmonary complications and acute respiratory failure (ARF) are among the most severe complications of hematologic malignancies and their treatment. When conventional respiratory support fails, extracorporeal membrane oxygenation (ECMO) may serve as a rescue therapy. However, its use in patients with hematologic malignancies remains controversial. The objective was to present a case series of veno-venous ECMO support for ARF in patients with hematologic malignancies and to evaluate the outcomes. Materials and methods. A retrospective study was conducted at the National Medical Research Center for Hematology and included adult patients with diseases of the hematopoietic system who required ECMO support for severe acute respiratory failure between 2018 and 2025. The clinical characteristics of patients, the stage and type of tumor disease, prior treatment, indices of organ dysfunction (APACHE II, SOFA), parameters of gas-exchange and hemostasis were evaluated. The etiology of pulmonary involvement was investigated, and central hemodynamic parameters, coagulation profiles and laboratory findings were monitored. Duration of ECMO support, the need for renal replacement therapy, treatment-related complications, and clinical outcomes were recorded. Descriptive statistical methods were applied; results are presented as medians with interquartile ranges. Overall survival was estimated using the Kaplan – Meier method. Results. The study cohort comprised 8 adult patients with different hematologic malignancies. Prior to ECMO initiation, all patients exhibited severe hypoxemia unresponsive to conventional respiratory support. Infectious lung injury of mixed etiology was identified in most cases, whereas neoplastic pulmonary infiltration was diagnosed in one patient. Thrombocytopenia (< 50×10⁹/L) was present in 63% of patients. The median duration of ECMO therapy was 13 days. Successful discontinuation of ECMO support was achieved in two patients. Major complications were predominantly hemorrhagic, including intracranial bleeding, and were frequently associated with significant coagulation disturbances complicating anticoagulation management. Conclusion. VV-ECMO may serve as a rescue therapy for selected patients with hematologic malignancies who develop refractory acute respiratory failure. However, its use is associated with a substantial risk of severe complications and poor outcomes. Careful patient selection is therefore essential and should consider the prognosis of the underlying disease, the likelihood of bone marrow recovery, and the potential effectiveness of antitumor therapy. Early identification of the cause of pulmonary injury and timely initiation of appropriate targeted treatment are critical factors influencing the success of ECMO support.
- Open Access
- 28 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 474-483-483
Efficacy of anti-CD19 CAR-T therapy after bispecific monoclonal antibody (CD19/CD3) therapy in a patient with relapsed Ph-positive acute lymphoblastic leukemia with a massive extramedullary component
Introduction. Patients with relapsed/refractory (r/r) Ph-positive acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options. New promising immunotherapies using CAR T cells or monoclonal antibodies (blinatumomab, inotuzumab/ozogamicin) in combination with tyrosine kinase inhibitors are being used for this group of patients. However, long-term results have not been studied when relapse or refractoriness develops after the use of one of these methods.Aim: to present a clinical observation of the use of anti-CD19 CAR T therapy after blinatumomab therapy in a patient with a relapsed course of Ph-positive acute lymphoblastic leukemia.Main findings. A 28-year-old patient was first diagnosed with Ph-positive B-ALL (transcript p210) in 2014. In the 1st line of treatment he was treated with therapy according to the protocol ‘ALL-2009’ with imatinib and allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, 2 months later the first molecular relapse was detected, and imatinib was replaced by dasatinib. In November 2016, a second relapse was diagnosed. In 2017, a third relapse with testicular involvement and T315I mutation was diagnosed, and therapy with ponatinib was initiated. In 2022, a 4th medullary relapse developed, and therapy with blinatumomab (5 courses) in combination with ponatinib was performed. After the 5th course of therapy, the appearance of leukaemides was noted, and asciminib was added to the therapy. However, no clinical effect was noted. The patient was treated with anti-CD19 CAR T therapy. A complete response to CAR T-cell therapy was confirmed on day 28 after CAR T administration. Further follow-up, over the course of one year, demonstrated stable clinical response and persistence of CD3-positive CAR T-cells. This case report of anti-CD19 CAR T cell therapy in a patient with CD19-positive combined relapse with massive extramedullary component after blinatumomab therapy demonstrated long-term efficacy with a 1-year follow-up.
- 28 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 474-483-483
Open AccessEfficacy of anti-CD19 CAR-T therapy after bispecific monoclonal antibody (CD19/CD3) therapy in a patient with relapsed Ph-positive acute lymphoblastic leukemia with a massive extramedullary component
Introduction. Patients with relapsed/refractory (r/r) Ph-positive acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options. New promising immunotherapies using CAR T cells or monoclonal antibodies (blinatumomab, inotuzumab/ozogamicin) in combination with tyrosine kinase inhibitors are being used for this group of patients. However, long-term results have not been studied when relapse or refractoriness develops after the use of one of these methods.Aim: to present a clinical observation of the use of anti-CD19 CAR T therapy after blinatumomab therapy in a patient with a relapsed course of Ph-positive acute lymphoblastic leukemia.Main findings. A 28-year-old patient was first diagnosed with Ph-positive B-ALL (transcript p210) in 2014. In the 1st line of treatment he was treated with therapy according to the protocol ‘ALL-2009’ with imatinib and allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, 2 months later the first molecular relapse was detected, and imatinib was replaced by dasatinib. In November 2016, a second relapse was diagnosed. In 2017, a third relapse with testicular involvement and T315I mutation was diagnosed, and therapy with ponatinib was initiated. In 2022, a 4th medullary relapse developed, and therapy with blinatumomab (5 courses) in combination with ponatinib was performed. After the 5th course of therapy, the appearance of leukaemides was noted, and asciminib was added to the therapy. However, no clinical effect was noted. The patient was treated with anti-CD19 CAR T therapy. A complete response to CAR T-cell therapy was confirmed on day 28 after CAR T administration. Further follow-up, over the course of one year, demonstrated stable clinical response and persistence of CD3-positive CAR T-cells. This case report of anti-CD19 CAR T cell therapy in a patient with CD19-positive combined relapse with massive extramedullary component after blinatumomab therapy demonstrated long-term efficacy with a 1-year follow-up.
- Open Access
- 23 October 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (3) , 441-452-452
Combination of ibrutinib and venetoclax followed by Chimeric Antigen Receptor T-cell therapy in the first line of treatment in an elderly patient with mantle cell lymphoma with hyperleukocytosis and mutation in the TP53 gene
Introduction. The tactics of therapy for elderly comorbid patients with mantle cell lymphoma with unfavorable prognosis factors (complex karyotype, 17p13 deletion, mutations in the TP53 gene) have not been developed. The use of intensive chemotherapy regimens and transplantation of allogeneic hematopoietic stem cells (allo-HSCT) is impossible due to severe comorbidity in elderly patients. A rational approach is the use of a combination of ibrutinib and venetoclax. As an alternative to allo-HSCT, a new option for elderly patients with poor prognostic factors is Chimeric Antigen Receptor T-cell therapy (CAR-T) cell therapy.Aim — to present the experience of using ibrutinib and venetoclax with CAR-T-cell therapy in the first line of treatment in an elderly patient with MCL with a mutation in the TP53 gene and hyperleukocytosis.Main findings. Patient M., 68 years old. The examination revealed hyperleukocytosis 978 × 109/L, anemia (55 g/L), thrombocytopenia (30 × 109/L), and splenomegaly 250 × 180 mm. According to the results of laboratory studies, the diagnosis of lymphoma from mantle cells with a complex karyotype, deletion 17p13, 13q14 and mutation p.R248W in exon 7 of the TP53 gene (VAF = 26 %) was verified. For cytoreductive purposes, two sessions of leukocytapheresis and prephase with cyclophosphamide (200 mg/m2) and dexamethasone (10 mg/m2) were performed. From day 3, therapy with ibrutinib 420 mg/day and venetoclax 100 mg/day was started. After 2 days, the leukocytes were 0.7 × 109/L, and the size of the spleen decreased, as a result of which the development of tumor lysis syndrome was noted. As a result of intensive therapy, the patient’s condition stabilized, which allowed him to resume treatment. After 7 days, the number of leukocytes was 2.5 × 109/L, neutrophils — 70 %, platelets — 90 × 109/L, hemoglobin — 95 g/L. According to immunophenotyping, the population of B-lymphocytes was 4 %. According to NGS data, the allelic load of the mutation in the TP53 gene is 0.8 %. The patient underwent anti-CD19 CAR-T-cell therapy and achieved complete remission. Three months after therapy, MRD remains-negative remission and the persistence of CAR-T cells is determined.
- 23 October 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (3) , 441-452-452
Open AccessCombination of ibrutinib and venetoclax followed by Chimeric Antigen Receptor T-cell therapy in the first line of treatment in an elderly patient with mantle cell lymphoma with hyperleukocytosis and mutation in the TP53 gene
Introduction. The tactics of therapy for elderly comorbid patients with mantle cell lymphoma with unfavorable prognosis factors (complex karyotype, 17p13 deletion, mutations in the TP53 gene) have not been developed. The use of intensive chemotherapy regimens and transplantation of allogeneic hematopoietic stem cells (allo-HSCT) is impossible due to severe comorbidity in elderly patients. A rational approach is the use of a combination of ibrutinib and venetoclax. As an alternative to allo-HSCT, a new option for elderly patients with poor prognostic factors is Chimeric Antigen Receptor T-cell therapy (CAR-T) cell therapy.Aim — to present the experience of using ibrutinib and venetoclax with CAR-T-cell therapy in the first line of treatment in an elderly patient with MCL with a mutation in the TP53 gene and hyperleukocytosis.Main findings. Patient M., 68 years old. The examination revealed hyperleukocytosis 978 × 109/L, anemia (55 g/L), thrombocytopenia (30 × 109/L), and splenomegaly 250 × 180 mm. According to the results of laboratory studies, the diagnosis of lymphoma from mantle cells with a complex karyotype, deletion 17p13, 13q14 and mutation p.R248W in exon 7 of the TP53 gene (VAF = 26 %) was verified. For cytoreductive purposes, two sessions of leukocytapheresis and prephase with cyclophosphamide (200 mg/m2) and dexamethasone (10 mg/m2) were performed. From day 3, therapy with ibrutinib 420 mg/day and venetoclax 100 mg/day was started. After 2 days, the leukocytes were 0.7 × 109/L, and the size of the spleen decreased, as a result of which the development of tumor lysis syndrome was noted. As a result of intensive therapy, the patient’s condition stabilized, which allowed him to resume treatment. After 7 days, the number of leukocytes was 2.5 × 109/L, neutrophils — 70 %, platelets — 90 × 109/L, hemoglobin — 95 g/L. According to immunophenotyping, the population of B-lymphocytes was 4 %. According to NGS data, the allelic load of the mutation in the TP53 gene is 0.8 %. The patient underwent anti-CD19 CAR-T-cell therapy and achieved complete remission. Three months after therapy, MRD remains-negative remission and the persistence of CAR-T cells is determined.
- Open Access
- 21 October 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (3) , 308-327-327
Intensive care of life-threatening complications in allogeneic hematopoietic stem cell recipients
Introduction. Life-threatening complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can have a significant influence on the short-term and long-term prognosis in recipients of hematopoietic stem cells (allo-HSCs).Aim — to determine the life-threatening complications and the risk factors of their occurrence and to evaluate the short-term and long-term prognosis in critically ill allo-HSCs recipients.Materials and methods. All patients over the age of 18 who underwent allo-HSCT from 01.01.2012 to 01.01.2022 were included in the retrospective study. Patients were divided into two groups: those who required intensive care unit (ICU) admission and those who did not require ICU admission. In the group of ICU admitted allo-HSCs recipients the reasons of ICU admission, timing of their occurrence and the results of life support were recorded. The risk factors of life-threatening complications occurrence and prognostic factors were analyzed.Results. In total, 174 (26.7 %) of 652 allo-HSCs recipients required ICU admission. The risk factors of life-threatening complications were: allo-HSCT in patients with acute leukemia who did not achieve complete remission (hazard ratio (HR) = 2.10; 95 % confidence interval (95% CI): 1.28–3.44; p = 0.003), allo-HSCT without conditioning in patients with hematopoietic aplasia after chemotherapy (HR = 30.63; 95% CI: 8.787–107.04; p < 0.001), graft failure (HR = 2.51; 95% CI: 1.58–3.97; p < 0.001) and poor graft function (HR = 2.85; 95% CI: 1.6–5.05; p < 0.001), acute graft versus host disease (GVHD) (HR = 2.04; 95% CI: 1.459–2.85; p < 0.001). The main reasons of ICU admission were sepsis and/or septic shock (SS) (27.9 %), acute respiratory failure (23.9 %), neurological disorders (17.7 %). The type and periods of allo-HSCT influenced the timing and structure of critical illnesses. The ICU mortality rate after all ICU admissions and readmissions was 59.8 % with a maximum follow-up of 9 years. The risk factors of ICU mortality were the occurrence of critical conditions after +30 days of allo-HSCT, the need for mechanical ventilation and vasopressors. The overall survival (OS) rate of ICU admitted allo-HSCs recipients was 13.8 %. Sepsis and/or SS that occurred in the early phase after allo-HSCT were characterized by the most favorable long-term outcome (OS — 43.8 %) among all complications of the peritransplantation period. The OS of patients discharged from the ICU was worse than OS of patients who did not require ICU admission (34.6 % vs. 58.3 %; p = 0.0013). Conclusion. Transplant centers should have a specialized ICU because more than a quarter of allo-HSCT recipients experience life-threatening complications at different allo-HSCT periods. Sepsis and SS occurring in the early pre-engraftment phase had a more favorable prognosis than other life-threatening complications. The long-term outcomes in allo-HSCs recipients who survived critical illness are worse than in recipients who did not require ICU admission.
- 21 October 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (3) , 308-327-327
Open AccessIntensive care of life-threatening complications in allogeneic hematopoietic stem cell recipients
Introduction. Life-threatening complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can have a significant influence on the short-term and long-term prognosis in recipients of hematopoietic stem cells (allo-HSCs).Aim — to determine the life-threatening complications and the risk factors of their occurrence and to evaluate the short-term and long-term prognosis in critically ill allo-HSCs recipients.Materials and methods. All patients over the age of 18 who underwent allo-HSCT from 01.01.2012 to 01.01.2022 were included in the retrospective study. Patients were divided into two groups: those who required intensive care unit (ICU) admission and those who did not require ICU admission. In the group of ICU admitted allo-HSCs recipients the reasons of ICU admission, timing of their occurrence and the results of life support were recorded. The risk factors of life-threatening complications occurrence and prognostic factors were analyzed.Results. In total, 174 (26.7 %) of 652 allo-HSCs recipients required ICU admission. The risk factors of life-threatening complications were: allo-HSCT in patients with acute leukemia who did not achieve complete remission (hazard ratio (HR) = 2.10; 95 % confidence interval (95% CI): 1.28–3.44; p = 0.003), allo-HSCT without conditioning in patients with hematopoietic aplasia after chemotherapy (HR = 30.63; 95% CI: 8.787–107.04; p < 0.001), graft failure (HR = 2.51; 95% CI: 1.58–3.97; p < 0.001) and poor graft function (HR = 2.85; 95% CI: 1.6–5.05; p < 0.001), acute graft versus host disease (GVHD) (HR = 2.04; 95% CI: 1.459–2.85; p < 0.001). The main reasons of ICU admission were sepsis and/or septic shock (SS) (27.9 %), acute respiratory failure (23.9 %), neurological disorders (17.7 %). The type and periods of allo-HSCT influenced the timing and structure of critical illnesses. The ICU mortality rate after all ICU admissions and readmissions was 59.8 % with a maximum follow-up of 9 years. The risk factors of ICU mortality were the occurrence of critical conditions after +30 days of allo-HSCT, the need for mechanical ventilation and vasopressors. The overall survival (OS) rate of ICU admitted allo-HSCs recipients was 13.8 %. Sepsis and/or SS that occurred in the early phase after allo-HSCT were characterized by the most favorable long-term outcome (OS — 43.8 %) among all complications of the peritransplantation period. The OS of patients discharged from the ICU was worse than OS of patients who did not require ICU admission (34.6 % vs. 58.3 %; p = 0.0013). Conclusion. Transplant centers should have a specialized ICU because more than a quarter of allo-HSCT recipients experience life-threatening complications at different allo-HSCT periods. Sepsis and SS occurring in the early pre-engraftment phase had a more favorable prognosis than other life-threatening complications. The long-term outcomes in allo-HSCs recipients who survived critical illness are worse than in recipients who did not require ICU admission.
- Open Access
- 6 July 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (2) , 216-239-239
Role of the intensive care in allogeneic hematopoietic stem cell transplantation
Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by life-threatening conditions.Aim — an analysis of the life-threatening complications in recipients of allogeneic hematopoietic stem cells (allo-HSCs)Main findings. From 10 to 50 % of allo-HSC recipients need to be admitted to the intensive care unit (ICU) due to the development of life-threatening complications. The reasons for ICU admission are acute respiratory failure, sepsis, graft-versus-host disease, veno-occlusive disease, thrombotic microangiopathy, cytokine release syndrome, engraftment syndrome, etc. Conditioning regimen, donor type, stem cell source, underlying disease state and patient comorbidity are the risk factors associated with development of life-threatening conditions. The main prognostic factors of unfavorable ICU outcomes in allo-HSC recipients are the severity of multiple organ dysfunction and the need for organ support.
- 6 July 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (2) , 216-239-239
Open AccessRole of the intensive care in allogeneic hematopoietic stem cell transplantation
Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by life-threatening conditions.Aim — an analysis of the life-threatening complications in recipients of allogeneic hematopoietic stem cells (allo-HSCs)Main findings. From 10 to 50 % of allo-HSC recipients need to be admitted to the intensive care unit (ICU) due to the development of life-threatening complications. The reasons for ICU admission are acute respiratory failure, sepsis, graft-versus-host disease, veno-occlusive disease, thrombotic microangiopathy, cytokine release syndrome, engraftment syndrome, etc. Conditioning regimen, donor type, stem cell source, underlying disease state and patient comorbidity are the risk factors associated with development of life-threatening conditions. The main prognostic factors of unfavorable ICU outcomes in allo-HSC recipients are the severity of multiple organ dysfunction and the need for organ support.
- Open Access
- 7 April 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (1) , 8-28-28
Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases
Introduction. The introduction of chimeric antigen receptor (CAR) T-cell therapy is a promising treatment of patients with relapsed or refractory (R/R) B-cell lymphoproliferative diseases (LPDs).Aim — to present the results of CAR-T-cell therapy of 6 adult patients with B-cell LPDs.Materials and methods. This is a pilot study conducted in adult patients with R/R or persistent minimal residual disease B-cell LPDs treated with CAR-T-cells. The study was approved by a local ethical committee of National Research Center for Hematology. Patients did not have alternative options for effective and safe treatment. All patients signed an informed consent. All patients were lymphodeplated with fl udarabine and cyclophosphamide for 4 days before the introduction of CAR-T-lymphocytes. Cytokine release syndrome (CRS) was prevented by tocilizumab on the day of CAR-T-cell administration. The effi cacy and safety of CAR-T-cell therapy was evaluated.Results. From 01.01.2020 to 01.01.2022, 10 CAR-T-cell infusions were performed for 6 adult patients (age 19–68 years, median — 32 years) with B-cell LPDs: 4 — R/R B-acute lymphoblastic leukemia, 1 — R/R diffuse large B-cell lymphoma, 1 — persistence of MRD in mantle cell lymphoma. In all patients with a R/R, median — 4 (2–5) lines of chemotherapy and/ or immunotherapy were performed before CAR-T-cell therapy. CD19 CAR-T-cells received 3 patients, CD19/CD22 CAR-Tcells — 2 patients, CD19 and CD20 CAR-T-cells received 1 patient. Autologous CAR-T-cells received 4 (66 %) patients, allogeneic CAR-T-cells received 1 patient, and one patient had two CAR-T-cell administrations — 1 autologous and 1 allogeneic. The median number of CAR-T-cells was 0.5 × 106 /kg (from 0.1 × 106 /kg to 3 × 106 /kg). In 7 (87.5 %) of the 8 cases after CAR-T-cell administration, overall response to therapy (complete or partial remission) was achieved, and complete remission was achieved in 6 (75 %) cases. Side effects were noted after 8 of 10 CAR-T-cell transfusions: CRS in 40 % (CRS 1 — 10 %, CRS 2 — 20 %, CRS 3 — 10 %), ICANS in 10 %, tumor lysis syndrome in 20 %, multi-organ dysfunction syndrome in 10 %. There were no lethal complications due to CAR-T-cell administrations. The median follow-up period was 6 (1–16) months. Of the 6 patients, 2 (33 %) died from relapses and progression of LPD. One (17 %) patient died in complete remission from infectious complications. Three (50 %) patients are observed till now. The median time of CAR-T-cell circulation was 33 (6– 60) days.Conclusion. CAR-T-cell therapy is a promising treatment for R/R B-cell LPDs and LPDs with persistence of MRD after cytoreductive therapy. This type of therapy requires a multidisciplinary approach.
- 7 April 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (1) , 8-28-28
Open AccessChimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases
Introduction. The introduction of chimeric antigen receptor (CAR) T-cell therapy is a promising treatment of patients with relapsed or refractory (R/R) B-cell lymphoproliferative diseases (LPDs).Aim — to present the results of CAR-T-cell therapy of 6 adult patients with B-cell LPDs.Materials and methods. This is a pilot study conducted in adult patients with R/R or persistent minimal residual disease B-cell LPDs treated with CAR-T-cells. The study was approved by a local ethical committee of National Research Center for Hematology. Patients did not have alternative options for effective and safe treatment. All patients signed an informed consent. All patients were lymphodeplated with fl udarabine and cyclophosphamide for 4 days before the introduction of CAR-T-lymphocytes. Cytokine release syndrome (CRS) was prevented by tocilizumab on the day of CAR-T-cell administration. The effi cacy and safety of CAR-T-cell therapy was evaluated.Results. From 01.01.2020 to 01.01.2022, 10 CAR-T-cell infusions were performed for 6 adult patients (age 19–68 years, median — 32 years) with B-cell LPDs: 4 — R/R B-acute lymphoblastic leukemia, 1 — R/R diffuse large B-cell lymphoma, 1 — persistence of MRD in mantle cell lymphoma. In all patients with a R/R, median — 4 (2–5) lines of chemotherapy and/ or immunotherapy were performed before CAR-T-cell therapy. CD19 CAR-T-cells received 3 patients, CD19/CD22 CAR-Tcells — 2 patients, CD19 and CD20 CAR-T-cells received 1 patient. Autologous CAR-T-cells received 4 (66 %) patients, allogeneic CAR-T-cells received 1 patient, and one patient had two CAR-T-cell administrations — 1 autologous and 1 allogeneic. The median number of CAR-T-cells was 0.5 × 106 /kg (from 0.1 × 106 /kg to 3 × 106 /kg). In 7 (87.5 %) of the 8 cases after CAR-T-cell administration, overall response to therapy (complete or partial remission) was achieved, and complete remission was achieved in 6 (75 %) cases. Side effects were noted after 8 of 10 CAR-T-cell transfusions: CRS in 40 % (CRS 1 — 10 %, CRS 2 — 20 %, CRS 3 — 10 %), ICANS in 10 %, tumor lysis syndrome in 20 %, multi-organ dysfunction syndrome in 10 %. There were no lethal complications due to CAR-T-cell administrations. The median follow-up period was 6 (1–16) months. Of the 6 patients, 2 (33 %) died from relapses and progression of LPD. One (17 %) patient died in complete remission from infectious complications. Three (50 %) patients are observed till now. The median time of CAR-T-cell circulation was 33 (6– 60) days.Conclusion. CAR-T-cell therapy is a promising treatment for R/R B-cell LPDs and LPDs with persistence of MRD after cytoreductive therapy. This type of therapy requires a multidisciplinary approach.
- Open Access
- 15 July 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (7) , 811-817
Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report
Сytokine release syndrome is the common complication of CAR-T therapy. We report a case of patient with B-cell acute lymphoblastic leukemia developing сytokine release syndrome with shock and multiple organ failure and requiring cytokine removal and hemodiafiltration. Remission of the disease was achieved after CAR-T therapy.
- 15 July 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (7) , 811-817
Open AccessExtracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report
Сytokine release syndrome is the common complication of CAR-T therapy. We report a case of patient with B-cell acute lymphoblastic leukemia developing сytokine release syndrome with shock and multiple organ failure and requiring cytokine removal and hemodiafiltration. Remission of the disease was achieved after CAR-T therapy.
- Open Access
- 9 November 2019
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 64 (3) , 297-316-316
ROTATION THROMBOELASTOMETRY FOR THE DIAGNOSIS OF FACTOR DEFICIENCY AND MANAGEMENT OF THE HEMOSTATIC THERAPY IN PATIENTS WITH INHERITED COAGULATION DISORDERS
Introduction. Rotation thromboelastometry (ROTEM) is a method for studying haemostasis at the place of providing care, which allows identification of disorders on the basis of extrinsic and / or intrinsic coagulation pathways.Aim. To study the possibility of using ROTEM for diagnosing the deficiency of individual blood coagulation factors, as well as for monitoring the efficacy and safety of haemostatic therapy in such coagulopathies.Materials and methods. The study included 9 patients with a congenital deficiency in various coagulation factors. The authors performed ROTEM, as well as coagulological tests to determine activated partial thromboplastin time, Quick’s value, fibrinogen and the plasma activity of coagulation factors FV, FVII, FVIII, FIX, FXI and FXII. In order to exclude the effects of heparin or hyperfibrinogenaemia, HEPTEM and / or FIBTEM were conducted. In order to identify the deficiency of individual coagulation factors, the authors used standard plasma samples and plasma deficient in one of the coagulation factors. The citrated blood under study was mixed with standard plasma and that deficient in one of the studied factors in a 2:1 ratio for subsequent repetition of the EXTEM and / or INTEM tests. Coagulation factor deficiency was confirmed by a change in the CT parameter.Results. Isolated prolongation of EXTEM CT was detected in the setting of FVII deficiency; while INTEM CT prolongation occurred under the deficiency of FVIII, FIX, FXI, FXII, with simultaneous EXTEM and INTEM CT prolongation being observed in the context of FVII deficiency. The test of a mixture of citrated blood and standard plasma revealed shortened EXTEM CT in the setting of FVII deficiency and shortened INTEM CT under the deficiency of FVIII, FIX, FXI, FXII, with the shortening of both EXTEM and INTEM CT being detected in the setting of FV deficiency. In a sample containing a mixture of whole blood and plasma deficient in the studied factor, CT remained prolonged or increased. Clinical examples of using ROTEM for diagnosing coagulation factor deficiency are presented.Conclusion. The normalisation of ROTEM parameters in a standard plasma sample along with the preservation of hypocoagulation in a factor-deficient plasma sample confirms the coagulation factor deficiency. ROTEM provides the possibility of monitoring the efficacy of haemostatic therapy for congenital deficiencies in individual blood coagulation factors.
- 9 November 2019
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 64 (3) , 297-316-316
Open AccessROTATION THROMBOELASTOMETRY FOR THE DIAGNOSIS OF FACTOR DEFICIENCY AND MANAGEMENT OF THE HEMOSTATIC THERAPY IN PATIENTS WITH INHERITED COAGULATION DISORDERS
Introduction. Rotation thromboelastometry (ROTEM) is a method for studying haemostasis at the place of providing care, which allows identification of disorders on the basis of extrinsic and / or intrinsic coagulation pathways.Aim. To study the possibility of using ROTEM for diagnosing the deficiency of individual blood coagulation factors, as well as for monitoring the efficacy and safety of haemostatic therapy in such coagulopathies.Materials and methods. The study included 9 patients with a congenital deficiency in various coagulation factors. The authors performed ROTEM, as well as coagulological tests to determine activated partial thromboplastin time, Quick’s value, fibrinogen and the plasma activity of coagulation factors FV, FVII, FVIII, FIX, FXI and FXII. In order to exclude the effects of heparin or hyperfibrinogenaemia, HEPTEM and / or FIBTEM were conducted. In order to identify the deficiency of individual coagulation factors, the authors used standard plasma samples and plasma deficient in one of the coagulation factors. The citrated blood under study was mixed with standard plasma and that deficient in one of the studied factors in a 2:1 ratio for subsequent repetition of the EXTEM and / or INTEM tests. Coagulation factor deficiency was confirmed by a change in the CT parameter.Results. Isolated prolongation of EXTEM CT was detected in the setting of FVII deficiency; while INTEM CT prolongation occurred under the deficiency of FVIII, FIX, FXI, FXII, with simultaneous EXTEM and INTEM CT prolongation being observed in the context of FVII deficiency. The test of a mixture of citrated blood and standard plasma revealed shortened EXTEM CT in the setting of FVII deficiency and shortened INTEM CT under the deficiency of FVIII, FIX, FXI, FXII, with the shortening of both EXTEM and INTEM CT being detected in the setting of FV deficiency. In a sample containing a mixture of whole blood and plasma deficient in the studied factor, CT remained prolonged or increased. Clinical examples of using ROTEM for diagnosing coagulation factor deficiency are presented.Conclusion. The normalisation of ROTEM parameters in a standard plasma sample along with the preservation of hypocoagulation in a factor-deficient plasma sample confirms the coagulation factor deficiency. ROTEM provides the possibility of monitoring the efficacy of haemostatic therapy for congenital deficiencies in individual blood coagulation factors.